Cannabis
CBD Skin Care Market Size is projected to reach USD 6466.43 million by 2030, growing at a CAGR of 32.15%: Straits Research
New York, United States, Sept. 20, 2023 (GLOBE NEWSWIRE) — Cannabidiol (CBD), derived from cannabis resin, is non-intoxicating. Cannabinoid (CBD) is most typically used with oils. CBD oil has anti-inflammatory, antioxidant, and skin-soothing properties. CBD oil is currently a popular ingredient in skin care and personal care products.
Since marijuana and cannabis-based cosmetics were legalized, CBD-infused skin care products have gained popularity. CBD-infused skin care products are popular because they relax. Anti-inflammatory and anti-oxidant properties make it a promising skin care ingredient. CBD-based skincare products can improve sleep and treat eczema, psoriasis, and acne. CBD-based skin care is popular among cosmetic brands. CBD-infused skin care is marketed as “natural cosmetics” CBD skin care products are expected to become popularity due to their versatility.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/cbd-skin-care-market/request-sample
Global CBD Skin Care Market: DRIVERS
- Cannabis-Derived Skin Care Products Are Gaining Popularity
A surge in the working population around the world has increased spending power and awareness of the range of commodities on the market, boosting sales of quality products. These factors have led to growing global demand for natural and organic personal care items.
People are becoming increasingly familiar with the benefits of CBD skin care products, such as CBD oil in their daily coffee, using it to their skin to relieve pain, consuming it to relieve anxiety, and using it in their sex life.
- Social-Media’s Impact on Skin Diseases
Because of pollution and UV radiation, which can cause skin burns, blackening, and cancer, consumers are turning to CBD-infused cosmetics and skincare products. Consumers’ increased acquaintance with the newest skin care products helps boost sales. Companies increasingly use celebrities to sell their products and spend a lot on advertising.
YouTube and Instagram are important influences on today’s society. These portals help people find CBD skin care products. Rising customer awareness of the benefits and availability of new products should benefit the global market in the futur
Global CBD Skin Care Market: KEY FUTURE OPPORTUNITIES
- Technological Advances and Mergers Create New Opportunities
Recent scientific advances have resulted to innovative CBD extracts and combinations for skin care. CBD-infused goods from multinational firms are capturing new markets and establishing new cash streams. Avon plans to develop vegan skin care products with CBD oil in 2020. As the cannabis beauty industry grows, component approaches vary. These factors boost market growth.
A growing number of technological innovations are driven by a desire to lower production costs and to foster sustainable growth from 2022 to 2030.
Report Scope
Report Metric | Details |
Market Size by 2030 | USD 6466.43 million |
Market Size in 2021 | USD 526.09 million |
CAGR | 32.15% (2022-2030) |
Historical Data | 2020-2021 |
Base Year | 2022 |
Forecast Period | 2023-2031 |
Forecast Units | Value (USD million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | By Technology, By Application, By Location |
Geographies Covered | North America, Europe, Asia-Pacific, LAME and Rest of the World |
Key Companies Profiled/Vendors | Kiehl’s LLC, Medical Marijuana, ENDOCA, Elixinol Global ltd, Lord Jones, Icanic Brands Company, Inc., LEEF Organics, The CBD Skincare Co, Kana Skincare, Apothecana, Josie Maran Cosmetics, FOLIUM BIOSCIENCES, CBD for life, Pacific Roots LLC, |
Key Market Opportunities | Technological Advances and Mergers Create New Opportunities |
Key Market Drivers | Cannabis-Derived Skin Care Products Are Gaining Popularity |
Buy Now Full Report @ https://straitsresearch.com/buy-now/cbd-skin-care-market
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa make up the CBD Skin Care Market.
North America, which had over 45% of the market in 2021, is expected to grow quickest. Demand for CBD skin care products in North America is expected to continue high due to a large client base and the legalization of marijuana. Due to legalization in 33 states and DC, the US possesses the world’s largest cannabis market. Cannabis legalization and well-known beauty product makers should boost industry growth in the next years.
CBD-infused skin care products may fuel US customer demand. The FDA Regulation of Cannabidiol (CBD) Products prohibits marijuana but not hemp or cannabis. Manufacturing and selling CBD derivatives is lawful. CBD derivatives may be used as lotions, serums, and ointments.
Asia Pacific will grow rapidly in the future years. China, India, Japan, and Korea are expected to see substantial growth. J-beauty and K-beauty lead the worldwide skincare market, despite cannabis being illegal in Asia. This market is expected to grow rapidly in Asia.
China is one of the main manufacturers of cannabis made from hemp, and the World Bank and IMF expect it to monopolize the market throughout the predicted period. China allows the production and sale of CBD products with a maximum 0.3% THC content from cannabis Sativa fruit, seed oil, and leaf extract. This benefits its use in high-end skincare and luxury cosmetics.
Due to changing legislation, India’s CBD skin care market is growing. The Narcotic Drugs and Psychotropic Substances Act of 1985 says it’s unlawful to produce cannabis in the U.S., although states can allow its commercial or research cultivation.
Key Highlights
- The Global CBD Skin Care Market size is predicted to reach at USD 6466.43 million by 2030, increasing at a CAGR of 32.15% from 2022 to 2030.
- By Source,the Global CBD Skin Care Market is segmented into Hemp and Marijuana. CBD skin care products derived from hemp maintained the biggest market share.
- By Type,the Global CBD Skin Care Market is segmented into Oils, Creams & Moisturizers, Masks & Serums, Cleansers, and Others. In 2021, the market was led by skin care oils containing CBD.
- By Region,the Global CBD Skin Care Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market share is dominated by North America.
Major Players in Global CBD Skin Care Market
- Kiehl’s LLC
- Medical Marijuana
- ENDOCA
- Elixinol Global ltd
- Lord Jones
- Icanic Brands Company, Inc.
- LEEF Organics
- The CBD Skincare Co
- Kana Skincare
- Apothecana
- Josie Maran Cosmetics
- FOLIUM BIOSCIENCES
- CBD for life
- Pacific Roots LLC
- Ecogen labs
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/cbd-skin-care-market/request-sample
Global CBD Skin Care Market: Segmentation
BY SOURCE
- Hemp
- Marijuana
BY TYPE
- Oils
- Creams & Moisturizers
- Masks & Serums
- Cleansers
- Others
BY GEOGRAPHY
- North America
- Europe
- Asia Pacific (APAC)
- Latin America
- Middle East and Africa (MEA)
TABLE OF CONTENT
- EXECUTIVE SUMMARY
- RESEARCH SCOPE & SEGMENTATION
- Research Objectives
- Market Definition
- Limitations & Assumptions
- Market Scope & Segmentation
- Currency & Pricing Considered
- MARKET OPPORTUNITY ASSESSMENT
-
- Emerging Regions / Countries
- Emerging Companies
- Emerging Applications / End Use
- Investment Landscape
- New Business Models / Revenue Streams
- TAM
- MARKET TRENDS
-
- Drivers
- Market Warning Factors
- Latest Macro Economic Indicators
- Geopolitical Impact
- Human Factors
- Technology Factors
- MARKET ASSESSMENT
-
- Porters Five Forces Analysis
- Value Chain Analysis
- Sales And Distribution Channel Analysis
- Average Pricing Analysis
- Patent Analysis
- M & A Agreements & Collabration Analysis
- Export Import Analysis
- ESG TRENDS
- GLOBAL CBD SKIN CARE MARKET SIZE ANALYSIS
-
- Global CBD Skin Care Market Introduction
- By Source
-
-
- Introduction
-
-
-
-
- Source By Value
-
-
-
-
- Hemp
-
-
-
-
- By Value
-
-
-
-
- Marijuana
-
-
-
-
- By Value
-
-
-
- By Type
-
-
- Introduction
-
-
-
-
- Type By Value
-
-
-
-
- Oils
-
-
-
-
- By Value
-
-
-
-
- Creams & Moisturizers
-
-
-
-
- By Value
-
-
-
-
- Masks & Serums
-
-
-
-
- By Value
-
-
-
-
- Cleansers
-
-
-
-
- By Value
-
-
-
-
- Others
-
-
-
-
- By Value
-
-
- NORTH AMERICA MARKET ANALYSIS
-
- Introduction
- By Source
-
-
- Introduction
-
-
-
-
- Source By Value
-
-
-
-
- Hemp
-
-
-
-
- By Value
-
-
-
-
- Marijuana
-
-
-
-
- By Value
-
-
-
- By Type
-
-
- Introduction
-
-
-
-
- Type By Value
-
-
-
-
- Oils
-
-
-
-
- By Value
-
-
-
-
- Creams & Moisturizers
-
-
-
-
- By Value
-
-
-
-
- Masks & Serums
-
-
-
-
- By Value
-
-
-
-
- Cleansers
-
-
-
-
- By Value
-
-
-
-
- Others
-
-
-
-
- By Value
-
-
-
- U.S.
-
-
- By Source
-
-
-
-
- Introduction
- Source By Value
- Hemp
- By Value
- Marijuana
- By Value
- Introduction
-
-
-
-
- By Type
-
-
-
-
- Introduction
- Type By Value
- Oils
- By Value
- Creams & Moisturizers
- By Value
- Masks & Serums
- By Value
- Cleansers
- By Value
- Others
- By Value
- Introduction
-
-
-
- Canada
- EUROPE MARKET ANALYSIS
-
- Introduction
- By Source
-
-
- Introduction
-
-
-
-
- Source By Value
-
-
-
-
- Hemp
-
-
-
-
- By Value
-
-
-
-
- Marijuana
-
-
-
-
- By Value
-
-
-
- By Type
- Introduction
- By Type
-
-
-
- Type By Value
-
-
-
-
- Oils
-
-
-
-
- By Value
-
-
-
-
- Creams & Moisturizers
-
-
-
-
- By Value
-
-
-
-
- Masks & Serums
-
-
-
-
- By Value
-
-
-
-
- Cleansers
-
-
-
-
- By Value
-
-
-
-
- Others
-
-
-
-
- By Value
-
-
-
- U.K.
-
-
- By Source
-
-
-
-
- Introduction
- Source By Value
- Hemp
- By Value
- Marijuana
- By Value
- Introduction
-
-
-
-
- By Type
-
-
-
-
- Introduction
- Type By Value
- Oils
- By Value
- Creams & Moisturizers
- By Value
- Masks & Serums
- By Value
- Cleansers
- By Value
- Others
- By Value
- Introduction
-
-
-
- Germany
- France
- Spain
- Italy
- Russia
- Nordic
- Benelux
- Rest Of Europe
- APAC MARKET ANALYSIS
-
- Introduction
- By Source
-
-
- Introduction
-
-
-
-
- Source By Value
-
-
-
-
- Hemp
-
-
-
-
- By Value
-
-
-
-
- Marijuana
-
-
-
-
- By Value
-
-
-
- By Type
-
-
- Introduction
-
-
-
-
- Type By Value
-
-
-
-
- Oils
-
-
-
-
- By Value
-
-
-
-
- Creams & Moisturizers
-
-
-
-
- By Value
-
-
-
-
- Masks & Serums
-
-
-
-
- By Value
-
-
-
-
- Cleansers
-
-
-
-
- By Value
-
-
-
-
- Others
-
-
-
-
- By Value
-
-
-
- China
-
-
- By Source
-
-
-
-
- Introduction
- Source By Value
- Hemp
- By Value
- Marijuana
- By Value
- Introduction
-
-
-
-
- By Type
-
-
-
-
- Introduction
- Type By Value
- Oils
- By Value
- Creams & Moisturizers
- By Value
- Masks & Serums
- By Value
- Cleansers
- By Value
- Others
- By Value
- Introduction
-
-
-
- Korea
- Japan
- India
- Australia
- Taiwan
- South East Asia
- Rest Of Asia-Pacific
- MIDDLE EAST AND AFRICA MARKET ANALYSIS
-
- Introduction
- By Source
-
-
- Introduction
-
-
-
-
- Source By Value
-
-
-
-
- Hemp
-
-
-
-
- By Value
-
-
-
-
- Marijuana
-
-
-
-
- By Value
-
-
-
- By Type
-
-
- Introduction
-
-
-
-
- Type By Value
-
-
-
-
- Oils
-
-
-
-
- By Value
-
-
-
-
- Creams & Moisturizers
-
-
-
-
- By Value
-
-
-
-
- Masks & Serums
-
-
-
-
- By Value
-
-
-
-
- Cleansers
-
-
-
-
- By Value
-
-
-
-
- Others
-
-
-
-
- By Value
-
-
-
- UAE
-
-
- By Source
-
-
-
-
- Introduction
- Source By Value
- Hemp
- By Value
- Marijuana
- By Value
- Introduction
-
-
-
-
- By Type
-
-
-
-
- Introduction
- Type By Value
- Oils
- By Value
- Creams & Moisturizers
- By Value
- Masks & Serums
- By Value
- Cleansers
- By Value
- Others
- By Value
- Introduction
-
-
-
- Turkey
- Saudi Arabia
- South Africa
- Egypt
- Nigeria
- Rest Of MEA
- LATAM MARKET ANALYSIS
-
- Introduction
- By Source
-
-
- Introduction
-
-
-
-
- Source By Value
-
-
-
-
- Hemp
-
-
-
-
- By Value
-
-
-
-
- Marijuana
-
-
-
-
- By Value
-
-
-
- By Type
-
-
- Introduction
-
-
-
-
- Type By Value
-
-
-
-
- Oils
-
-
-
-
- By Value
-
-
-
-
- Creams & Moisturizers
-
-
-
-
- By Value
-
-
-
-
- Masks & Serums
-
-
-
-
- By Value
-
-
-
-
- Cleansers
-
-
-
-
- By Value
-
-
-
-
- Others
-
-
-
-
- By Value
-
-
-
- Brazil
-
-
- By Source
-
-
-
-
- Introduction
- Source By Value
- Hemp
- By Value
- Marijuana
- By Value
- Introduction
-
-
-
-
- By Type
-
-
-
-
- Introduction
- Type By Value
- Oils
- By Value
- Creams & Moisturizers
- By Value
- Masks & Serums
- By Value
- Cleansers
- By Value
- Others
- By Value
- Introduction
-
-
-
- Mexico
- Argentina
- Chile
- Colombia
- Rest Of LATAM
- COMPETITIVE ASSESSMENT
-
- CBD Skin Care Market Share By Manufacturers
- CBD Skin Care Market Ranking By Revenue For Manufacturers
- Competitive Dashboard
- Product Mapping
- MARKET PLAYERS ASSESSMENT
-
- Kiehl’s LLC
-
-
- Overview
- Business Information
- Revenue
- ASP
- Gross Margin
- Swot Analysis
- Recent Developmments
-
-
- Medical Marijuana
- ENDOCA
- Elixinol Global Ltd
- Lord Jones
- Icanic Brands Company, Inc.
- LEEF Organics
- The CBD Skincare Co
- Kana Skincare
- Apothecana
- Josie Maran Cosmetics
- FOLIUM BIOSCIENCES
- CBD For Life
- Pacific Roots LLC
- Ecogen Labs
- RESEARCH METHODOLOGY
-
- Research Data
-
-
- Secondary Data
-
-
-
-
- Major Secondary Sources
- Key Data From Secondary Sources
-
-
-
-
- Primary Data
-
-
-
-
- Key Data From Primary Sources
- Breakdown Of Primaries
-
-
-
-
- Secondary And Primary Research
-
-
-
-
- Key Industry Insights
-
-
-
- Market Size Estimation
-
-
- Bottom-Up Approach
- Top-Down Approach
- Market Projection
-
-
- Research Assumptions
-
-
- Assumptions
-
-
- Limitations
- Risk Assessment
- APPENDIX
-
- Discussion Guide
- Customization Options
- Related Reports
- DISCLAIMER
Table of Content and Figure @ https://straitsresearch.com/report/cbd-skin-care-market/toc
News Media
Global CBD Skin Care Market Extends at a Healthy CAGR of 32.15%
Have a Look at the Related Research Report
Skincare Products Market: Information by Product Type (Facial Care, Lip Care, and Body Care), Category (Premium Skincare Products and Mass Skincare Products), and Region- Forecast till 2030
Skincare Body Products Market: Information by Gender (Male and Female), Product (Face Creams and Moisturizers), and Region — Forecast till 2030
Organic Skin Care Market: Information by Product (Face Cleanser, Face Serum), Distribution Channel (Online, Supermarket/Hypermarket), and Region — Forecast till 2030
Facial Skincare Products Market: Information by Product Type (Facial Cleanser, Toner, Facial Serum, Eye Creams), Distribution Channel (Specialty Stores), and Region — Forecast till 2030
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 905 0080 (the U.S.)
+91 8087085354 (APAC)
+44 203 695 0070 (the U.K.)
Email: [email protected]
Follow Us: LinkedIn | Facebook | Instagram | Twitter
Cannabis
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
Cannabis
IM Cannabis Reports First Quarter Financial Results
IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel-Hamas war.
TORONTO and GLIL YAM, Israel, May 8, 2024 /PRNewswire/ — IM Cannabis Corp. (the “Company” or “IMC“) (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated.
Q1 2024 Financial Highlights
- 13% Revenue increase vs. Q4 2023 of $12.1M vs. $10.7M and 4% decrease vs. Q1 2023 of $12.5M
- 125% Gross profit increase vs. Q4 2023 of $1.8M vs. $0.8 and 39% Gross profit decrease vs. Q1 2023 of $2.9M
- 29% decrease in operating expenses vs. Q1 2023 excluding the one-time Oranim revoke related losses of $4.6M vs. $6.5M and 14% increase including Oranim
- 12% increase of Non-IFRS Adjusted EBITDA loss to $2.1M
Operational Highlights
The Company intends to complete a non-brokered private placement (the “Offering“) of secured convertible debentures of the Company (each, a “Debenture“) for aggregate proceeds of up to C$2,500,000. The Debentures will mature on the date that is 12 months from the date of issuance and will not incur interest except in the event of default. The Debentures are being issued to holders of short term loans and obligations owed by the Company or its wholly owned subsidiaries. The principal of the Debenture may be converted into common shares in the Company (each, a “Share“) at a conversion price of $1.08 per Share.
Management Commentary
“With the April 1st cannabis legalization in Germany, we are augmenting our focus and resources on the German market, where we expect to see the biggest growth potential, and the best return on investment. While it is still too early to make any predictions, our sales in Germany almost doubled during the month of April,” said Oren Shuster, Chief Executive Officer of IMC. “Looking back on the first month post legalization in Germany, I see that we have the infrastructure and the supply agreements in place to continue delivering the accelerated growth we have already seen in April. We will also ensure that we have the necessary resources in place for success.”
“In 2023 we completely restructured, becoming a very lean and agile company, leaning into active cost management. This process is reflected in the numbers, our G&A decreased 27% vs Q1 2023” said Uri Birenberg, Chief Financial Officer of IMC. “While our results have recovered from the impact of the Israel-Hamas war, our revenue was still effected by both an unfavorable exchange rate, as well as price reductions to sell off inventory.”
Q1 2024 Conference Call
The Company will host a Zoom web conference call today at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
Q1 2024 Financial Results
- Revenues for the first quarter of 2024 were $12.1 million compared to $12.5 million in the first quarter of 2023, a decrease of 3%. The decrease is mainly due an exchange rate effect of about $0.2 million and decrease in avg. price per sale due to increased competition.
- Gross profit for the first quarter of 2024 was $1.8 million, compared to $2.9 million in Q1 2024, a decrease of 39%. The downside is attributed mainly to the slow-moving stock that was moved out at a lower price and an exchange rate difference totaling $0.4 million and $0.64 million cost of sales loss due to an inventory erase of the slow-moving stock. Company fair value adjustment was $0 and $0.4 million for the Q1 2024 and Q1 2023 respectively.
- Total Dried Flower sold in Q1 2024 was approximately 1,873 kg with an average selling price of $5.68 per gram, compared to approximately 1,842kg in Q1 2023, with an average selling price of $6.59 per gram. This difference is mainly due to increased competition within the retail segment, and mid-range stock discounts to move out slow moving stock.
- Total operating expenses in Q1 2024 were $7.4 million compared to $6.5 million in Q1 2023. The increase is due to the other operating expenses related to Oranim Deal revoke, with an expected losses of $2.8 million. Adjusting for this one-time losses, Q1 2024 operating expenses were $4.6 million compared to $6.5 million in Q1 2023, a decrease of 29%.
- G&A Expenses in Q1 2024 were $2.3 million, compared to $3.2 million in Q1 2023, a decrease of 28%. The decrease in the G&A expense is attributable mainly to salaries and professional services of $0.64 million.
- Selling and Marketing Expenses in Q1 2024 were $2.3 million, compared to $2.8 million in Q1 2023, a decrease of 18% mainly due to a decrease in Salaries and professional services of $0.5 million.
- Net Loss from continuing operations in Q1 2024 was $6.0 million, compared to $0.9 million in Q12023.
- Basic and diluted Loss per Share in Q1 2024 was $0.42, compared to a loss of $0.05 per Share in Q1 2023.
- Non-IFRS Adjusted EBITDA loss in Q1 2024 was $2.1 million, compared to an Adjusted EBITDA loss of $1.9 million in Q1 2023 an increase of 10%.
- Cash and Cash Equivalents as of March 31, 2024, were $1.0 million compared to $1.8 million in December 31, 2023.
- Total assets as of March 31, 2024, were $41.1 million, compared to $48.8 million in December 31, 2023, a decrease of 16%. The decrease is mainly attributed to the goodwill reduction due to Oranim agreement cancelation of about $2.8M, a reduction in Inventory of $2.1 million, reduction of Cash and cash equivalents of $0.8M and reduction in Trade payables of $1.2 million.
- Total Liabilities as of March 31, 2024, were $32.8 million, compared to $35.1 in December 31, 2023, a decrease of about 7%. The decrease was mainly due to the reduction in other accounts payables and accrued expenses of $1.8 million and reduction in the PUT option liability of $0.7 million.
The Company’s financial statements as of March 31, 2024 includes a note regarding the Company’s ability to continue as a going concern. The Company’s Q1 2024 financial results do not include any adjustments relating to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. For more information, please refer to the “Liquidity and Capital Resources” and “Risk Factors” sections in the Company’s management’s discussion and analysis for the quarter ended March 31, 2024.
Non-IFRS Measures
This press release makes reference to “Gross Margin” and “Adjusted EBITDA”, which are financial measures that are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as complementary information to the Company’s IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should neither be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.
For an explanation of how management defines Gross Margin and Adjusted EBITDA, see the Company’s management’s discussion and analysis for the period ended March 31, 2024, available under the Company’s SEDAR+ profile at www.sedarplus.ca on EDGAR at www.sec.gov/edgar.
We reconcile these non-IFRS financial measures to the most comparable IFRS measures as set out below.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||||
Canadian Dollars in thousands |
||||||
March 31, |
December 31, |
|||||
Note |
(Unaudited) |
|||||
ASSETS |
||||||
CURRENT ASSETS: |
||||||
Cash and cash equivalents |
$ 1,048 |
$ 1,813 |
||||
Trade receivables |
6,506 |
7,651 |
||||
Advances to suppliers |
780 |
936 |
||||
Other accounts receivable |
3,732 |
3,889 |
||||
Inventories |
3 |
7,901 |
9,976 |
|||
19,967 |
24,265 |
|||||
NON-CURRENT ASSETS: |
||||||
Property, plant and equipment, net |
4,939 |
5,058 |
||||
Investments in affiliates |
2,078 |
2,285 |
||||
Right-of-use assets, net |
1,243 |
1,307 |
||||
Intangible assets, net |
5,440 |
5,803 |
||||
Goodwill |
7,442 |
10,095 |
||||
21,142 |
24,548 |
|||||
Total assets |
$ 41,109 |
$ 48,813 |
||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||||
Canadian Dollars in thousands |
||||||
March 31, |
December 31, |
|||||
Note |
(Unaudited) |
|||||
LIABILITIES AND EQUITY |
||||||
CURRENT LIABILITIES:
|
||||||
Trade payables |
$ 9,511 |
$ 9,223 |
||||
Bank loans and credit facilities |
11,941 |
12,119 |
||||
Other accounts payable and accrued expenses |
4,440 |
6,218 |
||||
Accrued purchase consideration liabilities |
2,165 |
2,097 |
||||
PUT Option liability |
1,967 |
2,697 |
||||
Current maturities of operating lease liabilities |
461 |
454 |
||||
30,485 |
32,808 |
|||||
NON-CURRENT LIABILITIES:
|
||||||
Warrants measured at fair value |
4 |
137 |
38 |
|||
Operating lease liabilities |
744 |
815 |
||||
Long-term loans |
401 |
394 |
||||
Employee benefit liabilities, net |
96 |
95 |
||||
Deferred tax liability, net |
902 |
963 |
||||
2,280 |
2,305 |
|||||
Total liabilities |
32,765 |
35,113 |
||||
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: |
5 |
|||||
Share capital and premium |
253,887 |
253,882 |
||||
Translation reserve |
1,399 |
95 |
||||
Reserve from share-based payment transactions |
9,664 |
9,637 |
||||
Accumulated deficit |
(255,431) |
(249,145) |
||||
Total equity attributable to equity holders of the Company |
9,519 |
14,469 |
||||
Non-controlling interests |
(1,175) |
(769) |
||||
Total equity |
8,344 |
13,700 |
||||
Total liabilities and equity |
$ 41,109 |
$ 48,813 |
||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS |
||||||
AND OTHER COMPREHENSIVE INCOME (UNAUDITED) |
||||||
Canadian Dollars in thousands, except per share data |
||||||
Three months ended March 31, |
||||||
Note |
2024 |
2023 (*) |
||||
Revenues |
$ 12,063 |
$ 12,529 |
||||
Cost of revenues |
10,274 |
9,286 |
||||
Gross profit before fair value adjustments |
1,789 |
3,243 |
||||
Fair value adjustments: |
||||||
Realized fair value adjustments on inventory sold in the period |
(10) |
(339) |
||||
Total fair value adjustments |
(10) |
(339) |
||||
Gross profit |
1,779 |
2,904 |
||||
General and administrative expenses |
2,332 |
3,175 |
||||
Selling and marketing expenses |
2,292 |
2,805 |
||||
Restructuring expenses |
– |
283 |
||||
Share-based compensation |
32 |
258 |
||||
Other operating expenses |
9 |
2,753 |
– |
|||
Total operating expenses |
7,409 |
6,521 |
||||
Operating loss |
5,630 |
3,617 |
||||
Finance income |
4 |
(14) |
3,530 |
|||
Finance expense |
(487) |
(795) |
||||
Finance income, net |
(501) |
2,735 |
||||
Gain (loss) before income taxes |
(6,131) |
(882) |
||||
Income tax benefit |
(111) |
(16) |
||||
Net )loss( gain |
(6,020) |
(866) |
||||
Other comprehensive income that will not be reclassified to profit or loss in |
||||||
Total other comprehensive income that will not be reclassified to profit or loss |
67 |
36 |
||||
Exchange differences on translation to presentation currency |
1,330 |
(562) |
||||
Total other comprehensive income (loss) that will not be reclassified to profit |
1,397 |
(526) |
||||
Other comprehensive income that will be reclassified to profit or loss in |
||||||
Adjustments arising from translating financial statements of foreign operation |
(35) |
155 |
||||
Total other comprehensive income (loss) that will be reclassified to profit or loss |
(35) |
155 |
||||
Total other comprehensive income (loss) |
1,362 |
(371) |
||||
Total comprehensive loss |
$ (4,658) |
$ (1,237) |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS |
||||||
AND OTHER COMPREHENSIVE INCOME (UNAUDITED) |
||||||
Canadian Dollars in thousands, except per share data |
||||||
Three months ended March 31, |
||||||
Note |
2024 |
2023 (*) |
||||
Net income (loss) attributable to: |
||||||
Equity holders of the Company |
(5,623) |
(600) |
||||
Non-controlling interests |
(397) |
(266) |
||||
$ (6,020) |
$ (866) |
|||||
Total comprehensive income (loss) attributable to: |
||||||
Equity holders of the Company |
(4,252) |
(959) |
||||
Non-controlling interests |
(406) |
(278) |
||||
$ (4,658) |
$ (1,237) |
|||||
Net income (loss) per share attributable to equity holders of the Company: |
7 |
|||||
Basic and diluted (loss) gain per share (in CAD) |
$ (0.42) |
$ (0.05) |
||||
Earnings (loss) per share attributable to equity holders of the Company |
||||||
Basic and diluted (loss) gain per share (in CAD) |
$ (0.42) |
$ (0.05) |
||||
(*) See note 1 regarding figures disclosure. |
||||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
||||||
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
Canadian Dollars in thousands |
||||
Three months ended March 31, |
||||
2024 |
2023 (*) |
|||
Cash provided by operating activities: |
||||
Net income (loss) for the period |
$ (6,020) |
$ 43 |
||
Adjustments for non-cash items: |
||||
Fair value adjustment on sale of inventory |
10 |
339 |
||
Fair value adjustment on Warrants, investments and accounts receivable |
100 |
(3,636) |
||
Depreciation of property, plant and equipment |
147 |
174 |
||
Amortization of intangible assets |
452 |
456 |
||
Depreciation of right-of-use assets |
118 |
179 |
||
Impairment of goodwill |
2,753 |
– |
||
Finance expenses, net |
401 |
635 |
||
Deferred tax liability, net |
(69) |
(150) |
||
Share-based payment |
32 |
258 |
||
Restructuring expense |
– |
283 |
||
3,944 |
(1,462) |
|||
Changes in working capital: |
||||
Decrease (increase) in trade receivables |
1,332 |
1,937 |
||
Decrease (increase) in other accounts receivable and advances to suppliers |
159 |
(940) |
||
Decrease (increase) in inventories, net of fair value adjustments |
2,159 |
90 |
||
Decrease (increase) in trade payables |
663 |
(6,021) |
||
Changes in employee benefit liabilities, net |
– |
(22) |
||
Increase in other accounts payable and accrued expenses |
(2,745) |
(14) |
||
1,568 |
(4,970) |
|||
Taxes (paid) received |
(121) |
328 |
||
Net cash used in operating activities |
(629) |
(6,061) |
||
Cash flows from investing activities: |
||||
Purchase of property, plant and equipment |
(2) |
(411) |
||
Payment of purchase consideration |
– |
(56) |
||
Net cash used in investing activities |
$ (2) |
$ (467) |
||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
Canadian Dollars in thousands |
||||
Three months ended March 31, |
||||
2024 |
2023 |
|||
Cash flow from financing activities: |
||||
Proceeds from issuance of share capital, net of issuance costs |
176 |
825 |
||
Proceeds from issuance of warrants |
(176) |
7,027 |
||
Repayment of lease liability |
(118) |
(175) |
||
Interest paid – lease liability |
(15) |
(18) |
||
Receipt (repayment) of bank loan and credit facilities |
(2,856) |
(1,046) |
||
Cash paid for interest |
(444) |
(56) |
||
Proceeds from discounted checks |
2,581 |
|||
Net cash (used in) provided by financing activities |
(852) |
6,557 |
||
Effect of foreign exchange on cash and cash equivalents |
718 |
(1,059) |
||
Decrease in cash and cash equivalents |
(765) |
(1,030) |
||
Cash and cash equivalents at beginning of the period |
1,813 |
2,449 |
||
Cash and cash equivalents at end of the period |
$ 1,048 |
$ 1,419 |
||
Supplemental disclosure of non-cash activities: |
||||
Right-of-use asset recognized with corresponding lease liability |
$ 40 |
$ 49 |
||
Issuance of shares in payment of debt settlement to a non-independent director of the company |
$ – |
$ 222 |
||
(*) See note 1 regarding Figures disclosure. |
||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company also operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries. The Company has exited operations in Canada and considers these operations as discontinued.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the impact of the Israel-Hamas war on the Company, including its operations and the medical cannabis industry in Israel; the timing and impact of the legalization of medicinal cannabis in Germany, including, the Company having it “all in house”; the Company being positioned to take advantage of the legalization; the Company’s growth in 2024; the market growth for medicinal cannabis in Germany; the stated benefits of the Company’s EU-GMP processing facility and an EU-GDP logistics center; the Company to host a teleconference meeting as stated; and the Company’s stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to focus and resources to achieve sustainable and profitable growth in its highest value markets; the Company’s ability to mitigate the impact of the Israel-Hamas war on the Company; the Company’s ability to take advantage of the legalization of medicinal cannabis in Germany; the Company’s ability to host a teleconference meeting as stated; and the Company’s ability to carry out its stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to host a teleconference meeting as stated.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-reports-first-quarter-financial-results-302139688.html
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE2 weeks ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis3 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis2 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan1 day ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey